Floatz logo

Zorifertinib

EGFR Mutant Advanced Non-small Cell Lung Cancer

Alpha Biopharma (Jiangsu) Co., Ltd.Small moleculePhase 2/3Active
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
95/ 100

Competitive context

1205 Active assets in the EGFR Mutant Advanced Non-small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
d-0316
Betta Pharmaceuticals Co., Ltd.
Phase 2/3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB
Onartuzumab
Hoffmann-La Roche
Phase 3BBB

View all 50 →

Same molecule, other indications

Zorifertinib is also rated in:

metastatic malignant neoplasm in the brainDormant
BB
Indicative ·
67 / 100
View asset →
EGFR Gene MutationDormant
B
Indicative ·
58 / 100
View asset →
neoplastic meningitisDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →